Increased FADS2 expression has been observed in certain cancers and may offer a mechanism of increased metabolic plasticity [16], suggesting increased FADS1 and/or FADS2 activity may result in therapeutic resistance in relapsed AML. The gene discussed is FADS2; the disease is cancer.